申请人:Chinoin Gyogyszer es Vegyeszeti Termekek Gyara Rt
公开号:US04308270A1
公开(公告)日:1981-12-29
The invention concerns new compounds of the general formula (I) ##STR1## wherein R.sup.1 is hydrogen or phenyl optionally substituted by one or more of the following substituents: alkyl having 1 to 4 carbon atoms, halogen, alkoxy having 1 to 4 carbon atoms or nitro; R.sup.2 is alkyl having 1 to 4 carbon atoms, cycloalkyl having 5 to 7 carbon atoms or phenyl, optionally substituted with one or more of the following groups: alkyl having 1 to 4 carbon atoms, halogen, alkoxy having 1 to 4 carbon atoms or nitro; or R.sup.2 is a naphthyl group; R.sup.3 is alkyl having 1 to 4 carbon atoms, acyl or hydrogen; R.sup.4 hydrogen or alkyl having 1 to 4 carbon atoms; R.sup.5 is cycloalkyl having 5 to 7 carbon atoms, alkyl having 1 to 6 carbon atoms, phenyl-(C.sub.1-4 -alkyl) in which the phenyl moiety may optionally be substituted with alkoxy having 1 to 4 carbon atoms, halogen or nitro; or R.sup.4 and R.sup.5 together represent a group of the general formula (V) ##STR2## wherein R.sup.6 is hydrogen or alkoxy having 1 to 4 carbon atoms, m and n stand for 0, 1 or 2 and acid addition and quaternary salts thereof. The compounds of the general formula (I) are potent peripheral vasodilators and hypotensive agents. They increase the coronary blood flow and in addition to their slight antiinflammatory and diuretic acidivity possess strong antiarrhythmic properties. A process for the preparation of these compounds and pharmaceutical compositions containing them are also within the scope of the invention.
该发明涉及一般式(I)的新化合物,其中R.sup.1为氢或苯基,可以选择地被以下一种或多种取代基所取代:碳原子数为1至4的烷基,卤素,碳原子数为1至4的烷氧基或硝基;R.sup.2为碳原子数为1至4的烷基,碳原子数为5至7的环烷基或苯基,可选择地被以下一种或多种基团取代:碳原子数为1至4的烷基,卤素,碳原子数为1至4的烷氧基或硝基;或R.sup.2为萘基;R.sup.3为碳原子数为1至4的烷基,酰基或氢;R.sup.4为氢或碳原子数为1至4的烷基;R.sup.5为碳原子数为5至7的环烷基,碳原子数为1至6的烷基,苯基-(C.sub.1-4-烷基),其中苯基部分可以选择地被碳原子数为1至4的烷氧基,卤素或硝基取代;或R.sup.4和R.sup.5一起代表一般式(V)的基团,其中R.sup.6为氢或碳原子数为1至4的烷氧基,m和n代表0、1或2,以及其酸盐和季铵盐。一般式(I)的这些化合物是有效的外周血管扩张剂和降压剂。它们增加冠状血流,并除了具有轻微的抗炎和利尿作用外,还具有强烈的抗心律失常性能。该发明还涉及这些化合物的制备方法和含有它们的药物组合物。